Post-infection functional gastrointestinal disorders following coronavirus disease-19: A case-control study.
Beta coronavirus
COVID-19
Functional dyspepsia
Gastrointestinal symptoms
Gut-brain axis disorders
Irritable bowel syndrome
Post-infection IBS
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
revised:
03
10
2021
received:
21
06
2021
accepted:
13
10
2021
pubmed:
22
10
2021
medline:
11
3
2022
entrez:
21
10
2021
Statut:
ppublish
Résumé
Because acute infectious gastroenteritis may cause post-infection irritable bowel syndrome and functional dyspepsia and the severe acute respiratory syndrome coronavirus-2 affects gastrointestinal (GI) tract, coronavirus disease-19 (COVID-19) may cause post-infection-functional GI disorders (FGIDs). We prospectively studied the frequency and spectrum of post-infection-FGIDs among COVID-19 and historical healthy controls and the risk factors for its development. Two hundred eighty patients with COVID-19 and 264 historical healthy controls were followed up at 1 and 3 months using translated validated Rome Questionnaires for the development of chronic bowel dysfunction (CBD), dyspeptic symptoms, and their overlap and at 6-month for IBS, uninvestigated dyspepsia (UD) and their overlap. Psychological comorbidity was studied using Rome III Psychosocial Alarm Questionnaire. At 1 and 3 months, 16 (5.7%), 16 (5.7%), 11 (3.9%), and 24 (8.6%), 6 (2.1%), 9 (3.2%) of COVID-19 patients developed CBD, dyspeptic symptoms, and their overlap, respectively; among healthy controls, none developed dyspeptic symptoms and one developed CBD at 3 months (P < 0.05). At 6 months, 15 (5.3%), 6 (2.1%), and 5 (1.8%) of the 280 COVID-19 patients developed IBS, UD, and IBS-UD overlap, respectively, and one healthy control developed IBS at 6 months (P < 0.05 for all except IBS-UD overlap). The risk factors for post-COVID-19 FGIDs at 6 months included symptoms (particularly GI), anosmia, ageusia, and presence of CBD, dyspeptic symptoms, or their overlap at 1 and 3 months and the psychological comorbidity. This is the first study showing COVID-19 led to post-COVID-19 FGIDs. Post-COVID-19 FGIDs may pose a significant economic, social, and healthcare burden to the world.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Because acute infectious gastroenteritis may cause post-infection irritable bowel syndrome and functional dyspepsia and the severe acute respiratory syndrome coronavirus-2 affects gastrointestinal (GI) tract, coronavirus disease-19 (COVID-19) may cause post-infection-functional GI disorders (FGIDs). We prospectively studied the frequency and spectrum of post-infection-FGIDs among COVID-19 and historical healthy controls and the risk factors for its development.
METHODS
METHODS
Two hundred eighty patients with COVID-19 and 264 historical healthy controls were followed up at 1 and 3 months using translated validated Rome Questionnaires for the development of chronic bowel dysfunction (CBD), dyspeptic symptoms, and their overlap and at 6-month for IBS, uninvestigated dyspepsia (UD) and their overlap. Psychological comorbidity was studied using Rome III Psychosocial Alarm Questionnaire.
RESULTS
RESULTS
At 1 and 3 months, 16 (5.7%), 16 (5.7%), 11 (3.9%), and 24 (8.6%), 6 (2.1%), 9 (3.2%) of COVID-19 patients developed CBD, dyspeptic symptoms, and their overlap, respectively; among healthy controls, none developed dyspeptic symptoms and one developed CBD at 3 months (P < 0.05). At 6 months, 15 (5.3%), 6 (2.1%), and 5 (1.8%) of the 280 COVID-19 patients developed IBS, UD, and IBS-UD overlap, respectively, and one healthy control developed IBS at 6 months (P < 0.05 for all except IBS-UD overlap). The risk factors for post-COVID-19 FGIDs at 6 months included symptoms (particularly GI), anosmia, ageusia, and presence of CBD, dyspeptic symptoms, or their overlap at 1 and 3 months and the psychological comorbidity.
CONCLUSIONS
CONCLUSIONS
This is the first study showing COVID-19 led to post-COVID-19 FGIDs. Post-COVID-19 FGIDs may pose a significant economic, social, and healthcare burden to the world.
Identifiants
pubmed: 34672022
doi: 10.1111/jgh.15717
pmc: PMC8657345
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
489-498Subventions
Organisme : Department of Biotechnology, Government of India
ID : BT/PR40311/COD/139/9/2020
Informations de copyright
© 2021 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Indian J Gastroenterol. 2020 Jun;39(3):268-284
pubmed: 32749643
Indian J Gastroenterol. 2020 Jun;39(3):220-231
pubmed: 32783168
J Gastroenterol Hepatol. 2022 Mar;37(3):489-498
pubmed: 34672022
Am J Gastroenterol. 2021 Jan 1;116(1):4-7
pubmed: 33273261
J Trauma Stress. 2021 Feb;34(1):12-22
pubmed: 33045107
Gastroenterology. 2019 Jan;156(1):46-58.e7
pubmed: 30009817
Gastroenterology. 2016 Feb 18;:
pubmed: 27144620
Gastroenterology. 2016 May;150(6):1380-92
pubmed: 27147122
Histopathology. 2021 Mar;78(4):542-555
pubmed: 32926596
Gut. 2021 Oct;70(10):2015-2017
pubmed: 33402416
Front Immunol. 2021 Jan 29;11:621735
pubmed: 33584720
Sci Rep. 2021 Jun 25;11(1):13308
pubmed: 34172783
Gut. 2020 Aug;69(8):1543-1544
pubmed: 32312790
Gastroenterology. 2021 Jan;160(1):99-114.e3
pubmed: 32294476
J Neurogastroenterol Motil. 2015 Jan 1;21(1):83-92
pubmed: 25537673
Clin Transl Gastroenterol. 2020 Dec;11(12):e00259
pubmed: 33463978
Am J Gastroenterol. 2018 Sep;113(9):1363-1375
pubmed: 30171215
Indian J Gastroenterol. 2019 Apr;38(2):87-94
pubmed: 31073702
Gastroenterology. 2020 Jul;159(1):81-95
pubmed: 32251668
Gut. 2020 Jun;69(6):997-1001
pubmed: 32241899
J Gastroenterol Hepatol. 2020 May;35(5):712-721
pubmed: 32162356
Indian J Gastroenterol. 2020 Jun;39(3):236-242
pubmed: 32875524
Dig Liver Dis. 2020 Dec;52(12):1383-1389
pubmed: 33023827
Gastroenterology. 2017 Apr;152(5):1042-1054.e1
pubmed: 28069350
J Clin Exp Hepatol. 2020 Nov-Dec;10(6):622-628
pubmed: 32837095
Lancet Microbe. 2020 Nov;1(7):e290-e299
pubmed: 33015653
Clin Gastroenterol Hepatol. 2007 Apr;5(4):457-60
pubmed: 17289440
Clin Transl Gastroenterol. 2021 Apr 16;12(4):e00334
pubmed: 33878048
J Thromb Thrombolysis. 2021 Oct;52(3):692-707
pubmed: 34403043
J Neurogastroenterol Motil. 2016 Apr 30;22(2):240-7
pubmed: 26690730
Gastroenterology. 2020 Sep;159(3):944-955.e8
pubmed: 32442562
Indian J Gastroenterol. 2021 Apr;40(2):144-153
pubmed: 33226570
Afr J Emerg Med. 2020 Apr 2;:
pubmed: 32292690
Gastroenterology. 2016 May;150(6):1257-61
pubmed: 27147121